Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases.
The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
It also provides VRDN-006 a preclinical program for autoimmune disease.
In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -1.02 Increased by +19.69% | -0.89 Decreased by -14.61% |
| May 8, 24 | -0.79 Increased by +50.93% | -1.10 Increased by +28.18% |
| Feb 27, 24 | -1.35 Decreased by -19.47% | -1.00 Decreased by -35.00% |
| Nov 13, 23 | -1.09 Decreased by -26.74% | -1.27 Increased by +14.17% |
| Aug 8, 23 | -1.27 Decreased by -19.81% | -1.29 Increased by +1.55% |
| May 9, 23 | -1.61 Decreased by -64.29% | -1.02 Decreased by -57.84% |
| Mar 8, 23 | -1.13 Increased by +14.39% | -0.73 Decreased by -54.79% |
| Nov 14, 22 | -0.86 Increased by +31.20% | -1.02 Increased by +15.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 86.00 K Increased by +19.44% | -76.69 M Decreased by -60.91% | Decreased by -89.17 K% Decreased by -34.71% |
| Jun 30, 24 | 72.00 K Increased by 0.00% | -64.99 M Decreased by -18.03% | Decreased by -90.27 K% Decreased by -18.03% |
| Mar 31, 24 | 72.00 K Decreased by -26.53% | -48.54 M Increased by +28.66% | Decreased by -67.42 K% Increased by +2.90% |
| Dec 31, 23 | 72.00 K Decreased by -31.43% | -66.86 M Decreased by -57.30% | Decreased by -92.86 K% Decreased by -129.40% |
| Sep 30, 23 | 72.00 K Decreased by -93.97% | -47.66 M Decreased by -70.06% | Decreased by -66.19 K% Decreased by -2.72 K% |
| Jun 30, 23 | 72.00 K Decreased by -71.88% | -55.06 M Decreased by -87.17% | Decreased by -76.48 K% Decreased by -565.51% |
| Mar 31, 23 | 98.00 K Decreased by -54.63% | -68.05 M Decreased by -166.88% | Decreased by -69.43 K% Decreased by -488.22% |
| Dec 31, 22 | 105.00 K Decreased by -50.93% | -42.50 M Decreased by -46.84% | Decreased by -40.48 K% Decreased by -199.27% |